Telmisartan Tablets 20mg, 40mg, 80mg Oral Medications
Product : Telmisartan Tablets
Specification : 20mg, 40mg, 80mg
Standard : BP, USP
Packing : 10’s/blister
Telmisartan tablet is a non-peptide angiotensin II receptor (type
Telmisartan available as tablets for oral administration,
containing 20 mg, 40 mg or 80 mg of telmisartan.
Indications and Usage :
Telmisartan Tablets is indicated for the treatment of hypertension,
to lower blood pressure. Lowering blood pressure reduces the risk
of fatal and nonfatal cardiovascular events, primarily strokes and
myocardial infarctions. These benefits have been seen in controlled
trials of antihypertensive drugs from a wide variety of
pharmacologic classes including the class to which this drug
Control of high blood pressure should be part of comprehensive
cardiovascular risk management, including, as appropriate, lipid
control, diabetes management, antithrombotic therapy, smoking
cessation, exercise, and limited sodium intake. Many patients will
require more than one drug to achieve blood pressure goals. For
specific advice on goals and management, see published guidelines,
such as those of the National High Blood Pressure Education
Program`s Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with different mechanisms of action, have been shown in
randomized controlled trials to reduce cardiovascular morbidity and
mortality, and it can be concluded that it is blood pressure
reduction, and not some other pharmacologic property of the drugs,
that is largely responsible for those benefits. The largest and
most consistent cardiovascular outcome benefit has been a reduction
in the risk of stroke, but reductions in myocardial infarction and
cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the absolute risk increase per mmHg is
greater at higher blood pressures, so that even modest reductions
of severe hypertension can provide substantial benefit. Relative
risk reduction from blood pressure reduction is similar across
populations with varying absolute risk, so the absolute benefit is
greater in patients who are at higher risk independent of their
hypertension (for example, patients with diabetes or
hyperlipidemia), and such patients would be expected to benefit
from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as
monotherapy) in black patients, and many antihypertensive drugs
have additional approved indications and effects (e.g., on angina,
heart failure, or diabetic kidney disease). These considerations
may guide selection of therapy.
It may be used alone or in combination with other antihypertensive
2. Cardiovascular Risk Reduction
Telmisartan Tablets is indicated for reduction of the risk of
myocardial infarction, stroke, or death from cardiovascular causes
in patients 55 years of age or older at high risk of developing
major cardiovascular events who are unable to take ACE inhibitors.
High risk for cardiovascular events can be evidenced by a history
of coronary artery disease, peripheral arterial disease, stroke,
transient ischemic attack, or high-risk diabetes (insulin-dependent
or non-insulin dependent) with evidence of end-organ damage.
Telmisartan Tablets can be used in addition to other needed
treatment (such as antihypertensive, antiplatelet or lipid-lowering
Studies of telmisartan in this setting do not exclude the
possibility that telmisartan may not preserve a meaningful fraction
of the effect of the ACE inhibitor to which it was compared.
Consider using the ACE inhibitor first, and, if it is stopped for
cough only, consider re-trying the ACE inhibitor after the cough